Home / Pharmaceutical / Array BioPharma Inc. - Product Pipeline Review - 2015

Array BioPharma Inc. - Product Pipeline Review - 2015

Published: Nov 2015 | No Of Pages: 68 | Published By: Global Markets Direct

Array BioPharma Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Array BioPharma Inc. - Product Pipeline Review - 2015', provides an overview of the Array BioPharma Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Array BioPharma Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Array BioPharma Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Array BioPharma Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Array BioPharma Inc.'s pipeline products

Reasons to buy

- Evaluate Array BioPharma Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Array BioPharma Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Array BioPharma Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Array BioPharma Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Array BioPharma Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Array BioPharma Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents 2
List of Tables 4
List of Figures 4
P2D Bioscience Snapshot 5
P2D Bioscience Overview 5
Key Information 5
Key Facts 5
P2D Bioscience - Research and Development Overview 6
Key Therapeutic Areas 6
P2D Bioscience - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
P2D Bioscience - Pipeline Products Glance 11
P2D Bioscience - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
P2D Bioscience - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
P2D Bioscience - Drug Profiles 14
betahistine hydrochloride 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
2E-2 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
IDT 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
PD-2005 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
PD-2007 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
PD-2015 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
PD-2016 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
PD-2024 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PD-3766 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
PD-4048 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PD-4074 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Casin 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
P2D Bioscience - Pipeline Analysis 27
P2D Bioscience - Pipeline Products by Target 27
P2D Bioscience - Pipeline Products by Route of Administration 28
P2D Bioscience - Pipeline Products by Molecule Type 29
P2D Bioscience - Pipeline Products by Mechanism of Action 30
P2D Bioscience - Dormant Projects 31
P2D Bioscience - Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 3

Pfenex Inc., Key Information 5
Pfenex Inc., Key Facts 5
Pfenex Inc. - Pipeline by Indication, 2015 7
Pfenex Inc. - Pipeline by Stage of Development, 2015 8
Pfenex Inc. - Monotherapy Products in Pipeline, 2015 9
Pfenex Inc. - Partnered Products in Pipeline, 2015 10
Pfenex Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11
Pfenex Inc. - Phase I, 2015 12
Pfenex Inc. - IND/CTA Filed, 2015 13
Pfenex Inc. - Preclinical, 2015 14
Pfenex Inc. - Pipeline by Target, 2015 28
Pfenex Inc. - Pipeline by Route of Administration, 2015 29
Pfenex Inc. - Pipeline by Molecule Type, 2015 30
Pfenex Inc. - Pipeline Products by Mechanism of Action, 2015 31
Pfenex Inc. - Recent Pipeline Updates, 2015 32
Pfenex Inc. - Dormant Developmental Projects,2015 34

Array BioPharma Inc. - Pipeline by Top 10 Indication, 2015 8
Array BioPharma Inc. - Pipeline by Stage of Development, 2015 10
Array BioPharma Inc. - Monotherapy Products in Pipeline, 2015 11
Array BioPharma Inc. - Combination Treatment Modalities in Pipeline, 2015 12
Array BioPharma Inc. - Partnered Products in Pipeline, 2015 13
Array BioPharma Inc. - Out-Licensed Products in Pipeline, 2015 15
Array BioPharma Inc. - Pipeline by Top 10 Target, 2015 46
Array BioPharma Inc. - Pipeline by Top 10 Route of Administration, 2015 48
Array BioPharma Inc. - Pipeline by Top 10 Molecule Type, 2015 49
Array BioPharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 50

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +